The filing is a routine corporate update with no new material financial data. Monitor for the NMPA decision on F351 in early 2027 and IND filings for CG923308 and CG620953 in Q1 2027 as the next key catalysts.
Price Chart
Executive Summary
Gyre Therapeutics filed an 8-K furnishing an updated corporate presentation under Item 7.01. The presentation highlights the company's integrated U.S.-China R&D engine, its targeted protein degrader (TPD) and degrader-antibody conjugate (DAC) pipeline, and provides FY26 ETUARY total revenue guidance of $100.5-$111MM. Key upcoming catalysts include IND submissions for CDK2/Cyclin E degrader CG923308 and TYK2/JAK1 degrader CG620953 in Q1 2027, and a potential NMPA decision on F351 (hydronidone) for CHB-induced liver fibrosis in early 2027.
Key Facts
- FY26 ETUARY Total Revenue Guidance of $100.5-$111MM.
- NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China NMPA in May 2026; potential launch in early 2027.
- IND application submissions for CG923308 (CDK2/Cyclin E degrader) and CG620953 (TYK2/JAK1 degrader) planned for Q1 2027.
- CG009301 (GSPT1 degrader) Phase 1 dose escalation ongoing in China for hematologic malignancies.
- CG001419 (pan-TRK degrader) Phase 1 in healthy volunteers completed; Phase 2 for cancer-induced bone pain being planned.
- Corporate presentation is furnished as an exhibit and not deemed 'filed' for SEC liability purposes.
Financial Impact
FY26 ETUARY revenue guidance of $100.5-$111MM provides a baseline for cash flow to support R&D, but no new financial results or changes to prior guidance were disclosed.
Risk Factors
- Clinical development risk for all pipeline candidates; earlier study results may not be predictive of future results.
- Regulatory and commercial risk for F351 launch in China.
- Reliance on China operations for discovery and early development introduces geopolitical and operational risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-034401 |
| Document: 0001140361-26-034401-index.html | 0001140361-26-034401 |
| Document: 0001140361-26-034401.txt | 0001140361-26-034401 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $5.85 | awaiting T+20 | — | $6.07 (+3.76%) |
Sep 1, 2026 7w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.07 (−6.18%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.07 (−8.72%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.07 (+9.00%) |
Aug 4, 2026 11w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.07 (−1.30%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.07 (−4.26%) |
Jun 2, 2026 20w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.07 (+9.17%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.07 (−7.33%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.07 (−23.36%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.07 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers